Indo US Bio-Tech Reports Positive Q2 Results, Operating Profit Margin Reaches Record High

Indo US Bio-Tech, a microcap company in the agriculture industry, has recently announced its financial results for the quarter ending September 2024. The company's stock has been given a 'Hold' call by MarketsMOJO.

According to the financial report, Indo US Bio-Tech has shown positive performance in the second quarter of the fiscal year 2024-2025. The company's score has improved from 14 to 18 in the last three months, indicating an increase in efficiency.

One of the key factors contributing to this positive performance is the company's operating profit margin, which has reached its highest at 23.09% in the last five quarters. This shows that the company has become more efficient in its operations.

Moreover, the profit before tax less other income (PBT) has also seen a significant increase, reaching Rs 4.43 crore in the last quarter. This is a 37.5% growth compared to the average PBT of the previous four quarters. The profit after tax (PAT) has also shown a similar trend, with a growth of 37.0% over the average PAT of the previous four quarters.

The company's earnings per share (EPS) have also reached its highest at Rs 2.17 in the last five quarters, indicating an increase in profitability and higher earnings for shareholders.

However, one area of concern for Indo US Bio-Tech is its net sales, which have fallen by -11.8% compared to the average net sales of the previous four quarters. This shows a negative trend in sales in the near term.

Overall, Indo US Bio-Tech has shown positive financial performance in the recent quarter, with improvements in key areas such as operating profit margin and PBT. However, the company needs to address the decline in net sales to sustain its growth in the long term.